We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+61.37%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$66.9M
Cap. Flow
-$37.3M
Cap. Flow %
-11.13%
Top 10 Hldgs %
34.76%
Holding
938
New
616
Increased
74
Reduced
90
Closed
134

Top Buys

Rank Stock Value
1
HOOD icon
Robinhood
HOOD
+$16M
2
STM icon
STMicroelectronics
STM
+$13.6M
3
APH icon
Amphenol
APH
+$10.9M
4
STX icon
Seagate
STX
+$7.07M
5
F icon
Ford
F
+$6.02M

Top Sells

Rank Stock Value
1
SNDK
Sandisk
SNDK
+$18.4M
2
LITE icon
Lumentum
LITE
+$14.5M
3
AXTI icon
AXT Inc
AXTI
+$13.3M
4
TSEM icon
Tower Semiconductor
TSEM
+$11.9M
5
MU icon
Micron Technology
MU
+$10.9M

Sector Composition

Rank Sector Weight
1 Technology 38.35%
2 Healthcare 29.66%
3 Financials 6.33%
4 Miscellaneous 6.14%
5 Consumer Discretionary 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
126
ProQR Therapeutics
PRQR
$295M
$440K 0.13%
236,454
+190,387
+413% +$313K
EW icon
127
Edwards Lifesciences
EW
$51.7B
$438K 0.13%
4,846
-2,069
-30% -$173K
LNTH icon
128
Lantheus
LNTH
$6.59B
$433K 0.13%
3,903
+1,261
+48% +$117K
ABT icon
129
Abbott
ABT
$188B
$433K 0.13%
4,770
-2,009
-30% -$183K
BHVN icon
130
CALL
Biohaven
BHVN
$2.4B
$424K 0.13%
806
– –
UNCY icon
131
Unicycive Therapeutics
UNCY
$148M
$423K 0.13%
90,165
+63,338
+236% +$467K
SPRB
132
Spruce Biosciences
SPRB
$166M
$415K 0.12%
7,677
+5,149
+204% +$288K
AVR
133
Anteris Technologies
AVR
$850M
$413K 0.12%
41,940
-43,973
-51% -$334K
CAPR icon
134
PUT
Capricor Therapeutics
CAPR
$540M
$405K 0.12%
1,356
-222
-14% -$6.73K
REPL icon
135
CALL
Replimune Group
REPL
$1.44B
$397K 0.12%
1,774
+1,254
+241% +$7.67K
AVGO icon
136
Broadcom
AVGO
$1.7T
$396K 0.12%
+1,048
New +$420K
ARDX icon
137
Ardelyx
ARDX
$958M
$395K 0.12%
+77,371
New +$472K
QURE icon
138
uniQure
QURE
$3.11B
$394K 0.12%
8,545
+658
+8% +$17.2K
AA icon
139
Alcoa
AA
$13.5B
$391K 0.12%
+7,507
New +$503K
ROIV icon
140
Roivant Sciences
ROIV
$24.9B
$390K 0.12%
+11,020
New +$326K
CUE icon
141
Cue Biopharma
CUE
$201M
$389K 0.12%
12,332
+11,220
+1,009% +$254K
MLYS icon
142
Mineralys Therapeutics
MLYS
$2.5B
$389K 0.12%
14,410
-991
-6% -$27.2K
FBRX
143
DELISTED
Forte Biosciences
FBRX
$388K 0.12%
18,263
+11,519
+171% +$273K
AXSM icon
144
Axsome Therapeutics
AXSM
$10.9B
$385K 0.11%
+1,573
New +$341K
ERAS icon
145
Erasca
ERAS
$5.69B
$377K 0.11%
20,573
-7,697
-27% -$110K
PRTA icon
146
Prothena Corp
PRTA
$493M
$373K 0.11%
+38,100
New +$376K
TDS icon
147
Telephone and Data Systems
TDS
$4.35B
$368K 0.11%
+9,948
New +$419K
VYGR icon
148
Voyager Therapeutics
VYGR
$208M
$366K 0.11%
104,543
-2,551
-2% -$9.67K
COR icon
149
Cencora
COR
$64.4B
$357K 0.11%
1,260
+44
+4% +$12.7K
OCS icon
150
Oculis Holding
OCS
$676M
$355K 0.11%
+25,604
New +$581K
4 5
6
7 8

Similar funds

JWM
Jessup Wealth Management Dayton, Ohio $335M AUM 56.2% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $335M AUM 97.32% 1-Year Est. Return
TFA
TPG Financial Advisors Portland, Oregon $335M AUM 14.14% 1-Year Est. Return
SIM
Seaview Investment Managers Miami, Florida $335M AUM 47.2% 1-Year Est. Return
OWM
OneAscent Wealth Management Birmingham, Alabama $336M AUM 20.38% 1-Year Est. Return
SS
Spinecap SAS Paris, France $335M AUM 16.94% 1-Year Est. Return
BIA
BHK Investment Advisors Birmingham, Alabama $335M AUM 20.89% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

Persistent Asset Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Persistent Asset Partners held 938 positions worth $335M, up 25% from $268M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Persistent Asset Partners withdrew a net $37.3M in Q2 2026, closing 134 positions and reducing 90 holdings. Its most notable exit was Lumentum, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Persistent Asset Partners opened a new position in Robinhood worth $19.2M.

  • Persistent Asset Partners's largest Q2 2026 buy was Robinhood: 191,095 shares worth $19.2M.
  • Persistent Asset Partners added most to United Therapeutics in Q2 2026, an estimated $3.99M increase.
  • Persistent Asset Partners's biggest Q2 2026 reduction was Sandisk, cutting an estimated $18.4M.
  • Persistent Asset Partners fully exited Lumentum in Q2 2026, selling an estimated $14.5M.
  • Persistent Asset Partners's ten largest holdings make up 35% of its $335M portfolio in Q2 2026.
  • Persistent Asset Partners opened 616 new positions and closed 134 in Q2 2026.
  • Persistent Asset Partners's portfolio value rose 25% quarter-over-quarter to $335M.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.